Replies to post #631447 on NorthWest Biotherapeutics Inc (NWBO)

[reg2015]

so, did anyone ever get treated and has nwbo reapplied ? peace, reg2015

[pgsd]

"This approval has a term of five years, and can be re-applied for and re-issued at the end of that period" - (from 2014)

NWBO could re-apply however worth noting there are current plans for Significant hospital reform in Germany which could as they state "Given the broad scope of this reform, it will most likely also have an impact on the pharmaceutical and medical device industries, as well as other life sciences companies"

Given the broad scope of this reform, it will most likely also have an impact on the pharmaceutical and medical device industries, as well as other life sciences companies, including laboratory, diagnostics and digital health companies. Obviously, the products of all of these life sciences companies are used for hospital treatments. Some of the products are even used exclusively for inpatient treatment of patients in hospitals (e.g., implants, large diagnostic devices and many medicines).

Hence, if the hospital remuneration per patient treatment is reduced or the compensation system is modified, this will accordingly also affect the life sciences companies that sell the underlying medicines or medical devices to hospitals for these inpatient treatments. At this stage, it is not entirely clear how the remuneration and compensation systems will change and how these changes will impact certain treatments or products. Under the current DRG-based remuneration system, the costs of most products used for the treatment of a patient are compensated with the DRG-based fee. Insofar, it will be interesting to see how the future hospital remuneration system will handle this specific point and whether hospitals will experience more or less pressure with regard to the costs of products used in inpatient treatment. The publicly available key elements paper (Eckpunktepapier) is yet silent on this point.

Overall, life sciences companies should closely monitor these developments in Germany.

https://www.globalpolicywatch.com/2023/08/germany-plans-significant-hospital-reform-with-broad-impact-on-life-sciences-companies/
https://nwbio.com/nw-bio-announces-two-german-approvals-hospital-exemption-for-early-access-program-with-dcvax-l-and-eligibility-of-dcvax-l-for-reimbursement/

[HappyLibrarian]

It’s strange that NWBO that didn’t seem to mention these protectionist policies when they talked about HE or did shareholders miss that discussion?

Instead the focus back then after getting HE was on negotiating reimbursement from the sickness funds. There did not seem to be any discussion that Germany would have to change many rules just even make HE possible in practical terms.

The protectionist policies narrative is a much more recent revisionist history.